Provectus Biopharmaceuticals, Inc.
PVCT- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000315545
No open-market purchases or sales by Provectus Biopharmaceuticals, Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $8.97K in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Provectus Biopharmaceuticals, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 7 | 7 | 0 |
| Shares | 292.3K | 256.7K | −35.7K (−12.2%) |
| Value | $17.0K | $12.0K | −$5.00K (−29.4%) |
New holders (1)
Institutions that held Provectus Biopharmaceuticals, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| LBMC Investment Advisors, LLC | 22,000 | $1.00K | 0.00% |
Sold out (1)
Institutions that held Provectus Biopharmaceuticals, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Captrust Financial Advisors | 57,659 | $3.00K |